Mapi Pharma

Mapi Pharma is a clinical-stage pharmaceutical company developing proprietary drugs, including lifecycle management (LCM) products such as Depot long-acting injectables, complex active pharmaceutical ingredients (APIs), and formulations. The company's lead product is Glatiramer Acetate (GA, Copaxone®) Depot, a once-monthly 40mg GA intramuscular injection for the treatment of multiple sclerosis (market value of $200 billion). Mapi is also committed to developing Pregabalin ER for neuropathic pain and epilepsy, Paliperidone Palmitate and Buspirone ER for schizophrenia, as well as other long-acting Depot injectables.